Autologous bone marrow cell transplant for spastic cerebral palsy from brain hypoxia
Official title: Evaluation of the Efficacy of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in the Treatment of Cerebral Palsy Due to Brain Hypoxia: A Phase II Randomized Clinical Trial
Run by Vinmec Research Institute of Stem Cell and Gene Technology · NCT06629324 · Data updated 2026-11-12
This trial will try giving children aged 1 to 10 with spastic cerebral palsy caused by brain hypoxia an infusion of their own bone marrow mononuclear cells to see if their movement and muscle tightness improve.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 1 Year to 10 Years |
| Sex | All |
| Enrollment | 58 (estimated) |
| Sponsor | Vinmec Research Institute of Stem Cell and Gene Technology Academic / other |
| Locations | 2 sites (Hanoi and 1 other locations) |
| Status | Recruiting |
| Started | October 15, 2024 |
| Main results expected | October 15, 2026 |
| Study ends | January 31, 2027 |
| Registry record updated | January 22, 2026 |
| Trial ID | NCT06629324 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 1 to 10 with spastic cerebral palsy caused by brain hypoxia and GMFCS level II–V who are medically stable and meet laboratory and safety criteria are ideal candidates.
✕Probably not a fit
Children with non-hypoxic or non-spastic cerebral palsy, severe organ failure, active infections, coagulation disorders, spinal conditions preventing intrathecal procedures, or who fail hemoglobin and other safety thresholds are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase II randomized trial will enroll 58 children aged 1–10 with spastic cerebral palsy due to brain hypoxia and GMFCS levels II–V at Vinmec in Hanoi. Participants will be randomly assigned to receive autologous bone marrow mononuclear cell transplantation plus rehabilitation or a control regimen, with treatments delivered per protocol and follow-up visits over nine months after the first transplantation. Safety outcomes include monitoring adverse events and serious adverse events, and efficacy outcomes include changes in GMFM-88, GMFCS, Modified Ashworth Scale, and MACS/Mini-MACS scores. The trial builds on a Phase I safety study and aims to quantify functional gains and tone changes under standardized rehabilitation.
Why it matters
Potential benefit: If successful, this approach could reduce muscle spasticity and improve gross motor function and daily mobility for children with hypoxic spastic cerebral palsy, potentially improving quality of life.
How similar studies have gone: Small early-phase trials and the investigators' Phase I study have reported safety and some motor improvements with autologous bone marrow mononuclear cell therapy, but randomized evidence in larger samples is still limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age from 1 to 10 years, both genders; * Gross Motor Function Classification System (GMFCS): levels II to V; * Spastic cerebral palsy due to brain hypoxia. Exclusion Criteria: * Coagulation disorders; * Severe health conditions such as cachexia, heart failure, lung, liver, or kidney failure; or active infections; * Spinal injuries prevent the placement of a catheter through the spinal cavity; * Cancer; * HIV positive, active viral hepatitis; * Hemoglobin below 110 g/L.
Where it's running
-
Vinmec research Institute and Gene Technology
Hanoi, Vietnam Recruiting -
Vinmec Research Institute of Stem Cell and Gene Technology
Hanoi, Vietnam Not yet recruiting
Study contacts
- Principal investigator: Liem T Nguyen, MD., PhD — Vinmec Research Insitute of Stem Cell and Gene Technology
- Study coordinator: Liem T Nguyen, MD, PhD
- Email: v.liemnt@vinmec.com
- Phone: 800-555-5555
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Sensory Integration and Deep Pressure Therapy for Motor Coordination in Children with ASD
This study tests whether combining Sensory Integration Therapy with Deep Pressure Therapy can improve motor coordination and reduce repetitive behaviors in children aged 4–10 with autism.
-
Pupillometer screen to help identify autism in kids aged 2–4 during routine visits
A handheld pupillometer test is being tried to see if it can help identify autism in young children during regular pediatric visits.
-
Leopard: using multi-omics to boost genetic diagnosis for neurodevelopmental disorders
This study tests a multi-omics approach to find genetic explanations for neurodevelopmental disorders in people with moderate-to-severe intellectual disability.
-
Heart Rate Variability Biofeedback for Anxiety in Autistic Youth
This study tests a wearable heart rate variability biofeedback tool to see if it helps reduce anxiety in autistic teens.
-
Structured Sensory-Based Occupational Therapy for Children with Autism
This study tests a 12-week, 40-minute sensory-based occupational therapy program twice a week to see if it improves daily skills, sensory processing, movement, and eating in children aged 3-9 with autism.
-
Exergaming and Aerobic Exercise for Kids with Autism
This study tests whether adding exergames or aerobic exercise to a standard program helps improve sleep, movement skills, thinking skills, and brain activity in children with autism.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.